Oncoinvent ASA: Grant of share options to new Chief Medical Officer

Oslo, Norway, 28 October 2026: Oncoinvent has granted the new Chief Medical Officer (CMO) Dr Zuzana Jirakova Trnkova 20,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 67.35, equal to the volume weighted average share price the last day before the grant. See the attached form. Following the grant of the 20,000 share options referred to above, Zuzana Jirakova Trnkova holds 20,000 options in the Company.

Each option, when exercised, will give the right to acquire one share in the Company. The options are granted without consideration. No Options shall vest during the first 12 months following the date of the Grant Letter, 13/48 of the Options shall vest in the 13th month, and the remaining Options shall thereafter vest in equal monthly instalments of 1/48 (as long as the option holder is still employed). Options that have not been exercised will lapse 7 years after the date of grant.

The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The Board considers the option program terms and allocation to be at the market for comparable peers. 

PDMR Zuzana Jiráková Trnková.pdf

This information is subject to the disclosure requirements pursuant to Regulation (EU) 596/2014 (MAR) Article 19 and Section 5-12 of the Norwegian Securities Trading Act.